ITI-3000 Demonstrated a Favorable Safety and Tolerability Profile
Patients showed encouraging immunological responses, which will be further confirmed with a Phase II trial
ROCKVILLE, MD, USA I October 23, 2023 I Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced safety and tolerability results from its phase 1 clinical trial evaluating ITI-3000, a plasmid DNA (pDNA) vaccine, targeting patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer that is typically caused by the Merkel cell polyomavirus (MCPyV). ITI-3000 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) in November 2022.
“The reporting of results from our phase 1 trial of ITI-3000 in patients with MCC, marks the achievement of a significant milestone in our mission to create a therapeutic solution for this rare, yet highly aggressive skin cancer,” stated D.G. Kim, Chief Executive Officer of ITI. “As we expected, ITI-3000 proved to be safe and well tolerated in the study, with no dose-limiting toxicities, no reported treatment-related adverse events or serious adverse reactions. As we are encouraged by the immunological responses in patients, we look forward to continuing the development of ITI-3000. The advancement of this program is paving the way for the expansion of our pipeline via our UNITE® platform.”
The phase 1 clinical trial was a six-patient, single center, open label, first-in-human (FIH) study, investigating the safety, tolerability and immunogenicity of ITI-3000 in patients with polyomavirus-positive Merkel cell carcinoma (MCC). Participants received 4 doses of ITI-3000 vaccine, one 4 mg dose every month for four months. Participants in the study were those who are both diagnosed and had completed standard of care (SOC) surgical and/or radiation therapy at least one year prior to enrollment in the study, and who had no evidence of active disease (NEAD). Participants who were previously diagnosed with MCC and had recurrence but exhibited no evidence of active disease (NEAD) for more than two years prior to enrollment, were also included in the study.
Additional information regarding the phase 1 trial may be found at clinicaltrials.gov, using identifier: NCT05422781.
About ITI-3000
ITI-3000 leverages the company’s investigational UNiversal Intracellular Targeted Expression (UNITE®) platform, powered by LAMP (Lysosome Associated Membrane Protein), which fuses sequences from the mutated form of the large T antigen (LT) of the MCPyV into the sequence of the LAMP-1 gene. This lysosomal targeting technology has been shown to result in enhanced antigen presentation and a potent immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical-stage biotechnology company pioneering the development of vaccines through its proprietary technology platform UNITE®, which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. ITI is primarily focused on applying the UNITE platform to oncology indications, where it could potentially have broad applications, including development of antigen-derived antibodies as biologics in a number of cancers. The company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
SOURCE: Immunomic Therapeutics
Post Views: 251
ITI-3000 Demonstrated a Favorable Safety and Tolerability Profile
Patients showed encouraging immunological responses, which will be further confirmed with a Phase II trial
ROCKVILLE, MD, USA I October 23, 2023 I Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced safety and tolerability results from its phase 1 clinical trial evaluating ITI-3000, a plasmid DNA (pDNA) vaccine, targeting patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer that is typically caused by the Merkel cell polyomavirus (MCPyV). ITI-3000 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) in November 2022.
“The reporting of results from our phase 1 trial of ITI-3000 in patients with MCC, marks the achievement of a significant milestone in our mission to create a therapeutic solution for this rare, yet highly aggressive skin cancer,” stated D.G. Kim, Chief Executive Officer of ITI. “As we expected, ITI-3000 proved to be safe and well tolerated in the study, with no dose-limiting toxicities, no reported treatment-related adverse events or serious adverse reactions. As we are encouraged by the immunological responses in patients, we look forward to continuing the development of ITI-3000. The advancement of this program is paving the way for the expansion of our pipeline via our UNITE® platform.”
The phase 1 clinical trial was a six-patient, single center, open label, first-in-human (FIH) study, investigating the safety, tolerability and immunogenicity of ITI-3000 in patients with polyomavirus-positive Merkel cell carcinoma (MCC). Participants received 4 doses of ITI-3000 vaccine, one 4 mg dose every month for four months. Participants in the study were those who are both diagnosed and had completed standard of care (SOC) surgical and/or radiation therapy at least one year prior to enrollment in the study, and who had no evidence of active disease (NEAD). Participants who were previously diagnosed with MCC and had recurrence but exhibited no evidence of active disease (NEAD) for more than two years prior to enrollment, were also included in the study.
Additional information regarding the phase 1 trial may be found at clinicaltrials.gov, using identifier: NCT05422781.
About ITI-3000
ITI-3000 leverages the company’s investigational UNiversal Intracellular Targeted Expression (UNITE®) platform, powered by LAMP (Lysosome Associated Membrane Protein), which fuses sequences from the mutated form of the large T antigen (LT) of the MCPyV into the sequence of the LAMP-1 gene. This lysosomal targeting technology has been shown to result in enhanced antigen presentation and a potent immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical-stage biotechnology company pioneering the development of vaccines through its proprietary technology platform UNITE®, which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. ITI is primarily focused on applying the UNITE platform to oncology indications, where it could potentially have broad applications, including development of antigen-derived antibodies as biologics in a number of cancers. The company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
SOURCE: Immunomic Therapeutics
Post Views: 251